BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 36942414)

  • 21. [Engineering memory-rich CAR-T cells by a piggyBac transposon system].
    Yagyu S
    Rinsho Ketsueki; 2023; 64(5):418-426. PubMed ID: 37271534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies.
    Wang H; Tang L; Kong Y; Liu W; Zhu X; You Y
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CAR-Ts: new perspectives in cancer therapy.
    Abrantes R; Duarte HO; Gomes C; Wälchli S; Reis CA
    FEBS Lett; 2022 Feb; 596(4):403-416. PubMed ID: 34978080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook.
    Zhang H; Zhu S; Deng W; Li R; Zhou H; Xiong H
    Front Immunol; 2022; 13():887471. PubMed ID: 35935930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CAR-NK cells: A promising cellular immunotherapy for cancer.
    Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
    EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ophthalmic Implications of Chimeric Antigen Receptor T-Cell Therapy.
    Chodnicki KD; Prasad S
    Semin Ophthalmol; 2021 May; 36(4):329-334. PubMed ID: 33689570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
    Yu S; Yi M; Qin S; Wu K
    Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Sun C; Li D; Wang Z
    Immunotherapy; 2024 Mar; 16(5):331-340. PubMed ID: 38264838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions.
    Salaroli A; Spilleboudt C; Bron D; Lewalle P
    Curr Opin Oncol; 2020 Sep; 32(5):434-441. PubMed ID: 32796231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paving the road to make chimeric antigen receptor-T-cell therapy effective against solid tumors.
    Adachi K; Tamada K
    Cancer Sci; 2022 Dec; 113(12):4020-4029. PubMed ID: 36047968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors.
    Sun Z; Li R; Shen Y; Tan S; Ding N; Xu R; Wang X; Wei J; Liu B; Meng F
    J Hematol Oncol; 2022 Mar; 15(1):29. PubMed ID: 35303900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deletion of Cbl-b inhibits CD8
    Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent perspective on CAR and Fcγ-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes.
    Marei HE; Althani A; Caceci T; Arriga R; Sconocchia T; Ottaviani A; Lanzilli G; Roselli M; Caratelli S; Cenciarelli C; Sconocchia G
    Biochem Pharmacol; 2019 Aug; 166():335-346. PubMed ID: 31176617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.
    Verma A; Rafiq S
    Cancer Treat Res; 2022; 183():161-184. PubMed ID: 35551659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cell therapy's poster child: Chimeric antigen receptor T cell therapy].
    Qian L; Chen J; Wu X; Jing R; Sun J
    Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2339-2349. PubMed ID: 31880140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CAR T-cell therapy: Reprogramming patient's immune cell to treat cancer.
    Mavi AK; Gaur S; Gaur G; Babita ; Kumar N; Kumar U
    Cell Signal; 2023 May; 105():110638. PubMed ID: 36822565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.